Bank of New York Mellon Corp increased its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 1.1% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 538,156 shares of the biopharmaceutical company’s stock after buying an additional 5,616 shares during the period. Bank of New York Mellon Corp owned about 0.44% of Celldex Therapeutics worth $1,943,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently bought and sold shares of CLDX. Canada Pension Plan Investment Board boosted its position in Celldex Therapeutics by 106.7% in the first quarter. Canada Pension Plan Investment Board now owns 203,800 shares of the biopharmaceutical company’s stock worth $736,000 after buying an additional 105,200 shares during the last quarter. Hikari Power Ltd bought a new position in Celldex Therapeutics during the first quarter worth $181,000. Meditor Group Ltd bought a new position in Celldex Therapeutics during the first quarter worth $14,966,000. Creative Planning boosted its position in Celldex Therapeutics by 6.1% in the first quarter. Creative Planning now owns 71,420 shares of the biopharmaceutical company’s stock worth $258,000 after buying an additional 4,084 shares during the last quarter. Finally, Teachers Advisors LLC boosted its position in Celldex Therapeutics by 0.9% in the fourth quarter. Teachers Advisors LLC now owns 167,582 shares of the biopharmaceutical company’s stock worth $593,000 after buying an additional 1,433 shares during the last quarter. 65.83% of the stock is currently owned by hedge funds and other institutional investors.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) traded down 1.98% on Monday, hitting $2.47. The stock had a trading volume of 919,845 shares. Celldex Therapeutics, Inc. has a 52-week low of $2.20 and a 52-week high of $5.02. The company’s market cap is $309.01 million. The firm’s 50-day moving average is $2.44 and its 200-day moving average is $3.05.
Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.28). The firm had revenue of $1.53 million during the quarter, compared to analyst estimates of $0.57 million. Celldex Therapeutics had a negative return on equity of 53.10% and a negative net margin of 1,825.82%. Equities research analysts anticipate that Celldex Therapeutics, Inc. will post ($1.10) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://stocknewstimes.com/2017/08/07/bank-of-new-york-mellon-corp-buys-5616-shares-of-celldex-therapeutics-inc-cldx-updated-updated.html.
A number of research analysts have recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Celldex Therapeutics in a research report on Tuesday, August 1st. BidaskClub cut Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. Zacks Investment Research cut Celldex Therapeutics from a “buy” rating to a “sell” rating in a research report on Monday, July 17th. Aegis reaffirmed a “buy” rating on shares of Celldex Therapeutics in a research report on Thursday, June 29th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Celldex Therapeutics in a research report on Tuesday, June 6th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. Celldex Therapeutics presently has a consensus rating of “Hold” and an average price target of $7.32.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
